Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men
Pignone, M., Earnshaw, S., McDade, C., & Pletcher, M. J. (2013). Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men. Journal of General Internal Medicine, 28(11), 1483-1491. DOI: 10.1007/s11606-013-2465-6
Recent data suggest that aspirin may be effective for reducing cancer mortality.
To examine whether including a cancer mortality-reducing effect influences which men would benefit from aspirin for primary prevention.
We modified our existing Markov model that examines the effects of aspirin among middle-aged men with no previous history of cardiovascular disease or diabetes. For our base case scenario of 45-year-old men, we examined costs and life-years for men taking aspirin for 10 years compared with men who were not taking aspirin over those 10 years; after 10 years, we equalized treatment and followed the cohort until death. We compared our results depending on whether or not we included a 22 % relative reduction in cancer mortality, based on a recent meta-analysis. We discounted costs and benefits at 3 % and employed a third party payer perspective.
Cost per quality-adjusted life year (QALY) gained.
When no effect on cancer mortality was included, aspirin had a cost per QALY gained of 22,492at5 43,342). Results were somewhat sensitive to utility of taking aspirin daily; risk of death after myocardial infarction; and effects of aspirin on stroke, myocardial infarction, and sudden death. However, aspirin remained cost-saving or cost-effective (< $50,000 per QALY) in probabilistic analyses (59 % with no cancer effect included; 96 % with cancer effect) for men at 5 % risk.
Including an effect of aspirin on cancer mortality influences the threshold for prescribing aspirin for primary prevention in men. If such an effect is real, many middle-aged men at low cardiovascular risk would become candidates for regular aspirin use.